NeoRas
Neoadjuvant daraxonrasib plus gemcitabine/nab-paclitaxel (GnP) as induction or consolidation treatment in combination with MRI-guided online adaptive radiotherapy (oMRgRT) in participants with borderline resectable pancreatic cancer (BR-PDAC) - NeoRas: a prospective, randomized, multicenter, phase I trial of the AIO pancreatic cancer group and the Interdisciplinary Working Group Visceral Oncology (IAG-VO) of the German Cancer Society
I
interventionell
National
Experimental intervention Arm A (radiotherapy first): MRI-guided online adaptive radiotherapy (oMRgRT; 5 × 6.6 Gy with a simultaneous integrated boost of 5 × 8 Gy to the pancreatic tumor and adjacent vessels, every other day), followed after a 2-week interval by 2 months (2 cycles of 28 days) of preoperative gemcitabine/nab-paclitaxel (days 1 and 15 of each cycle) in combination with daraxonrasib 200 mg once daily, followed by daraxonrasib monotherapy 300 mg once daily until 2 weeks before surgery. Tumor resection 6–8 weeks after completion of neoadjuvant treatment. Postoperative treatment (start within 12 weeks after surgery): 4 months of gemcitabine/nab-paclitaxel plus daraxonrasib 200 mg once daily, followed by daraxonrasib monotherapy 300 mg once daily, for a total postoperative treatment duration of 24 months.
Experimental intervention Arm B (induction chemotherapy first): 2 months (2 cycles of 28 days) of preoperative gemcitabine/nab-paclitaxel (days 1 and 15 of each cycle) in combination with daraxonrasib 200 mg once daily, followed after a 2-week interval by the oMRgRT schedule defined above (5 × 6.6 Gy, SIB 5 × 8 Gy, every other day; daraxonrasib is paused from the end of cycle 2 until the last radiotherapy fraction), followed by daraxonrasib monotherapy 300 mg once daily until 2 weeks before surgery. Tumor resection 6–8 weeks after completion of neoadjuvant treatment and postoperative treatment as in Arm A.
Status: In Vorbereitung
Zeitraum
2027
2031
Zentren
5
Keine Zentren gesucht
Patienten
50
09.11.2026
Klinische Settings
I, II, IIA, IIB, IIC, III, IIIA, IIIB, IIIC
peri-operativ
kurativ
Beteiligte
AIO-Arbeitsgruppen
Sponsor
Universitätsklinikum Ulm (operative Koordination: Zentrum für Klinische Studien Ulm)
Kooperierende Fachgesellschaft(en)
Interdisziplinäre Arbeitsgruppe Viszeralonkologie – IAG VO
Assoziation Chirurgische Onkologie (ACO)
Arbeitsgemeinschaft Radiologische Onkologie (ARO)
Förderer
Geplant DFG
Identifier
AIO-PAK-0125/ass
Kontakt
Leitung
Prof. Dr. med. Thomas Seufferlein
Ansprechpartner*in
Dr. med. Thomas Ettrich
Telefon +49 731 50044774
E-Mail thomas.ettrich@uniklinik-ulm.de